Varenicline Tartrate

• CAT Number: I003379
• CAS Number: 375815-87-5
• Molecular Formula: C13H13N3 • C4H6O6
• Molecular Weight: 361.39
• Purity: ≥95%
• Synonyms: CP 526555;Champix
• Target: Neuronal Signaling
• Solubility: H2O: 72 mg/mL, DMSO: ＜1 mg/mL
• Storage: 3 years -20C powder
• IUPAC Name: (2R,3R)-2,3-dihydroxybutanedioic acid;5,8,14-triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaene
• InChI: InChI=1S/C13H13N3.C4H6O6/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1;5-1(3(7)8)2(6)4(9)10/h1-2,4-5,8-9,14H,3,6-7H2;1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1
• InChIKey: TWYFGYXQSYOKLK-UHFFFAOYSA-N
• SMILES: C1C2CNCC1C3=CC4=NC=CN=C4C=C23.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O

Varenicline Tartrate(CAT: I003379) is a selective partial agonist of the α4β2 nicotinic acetylcholine receptors (nAChRs) in the brain. By partially stimulating these receptors, it reduces nicotine cravings and withdrawal symptoms while simultaneously blocking nicotine from binding to these receptors, diminishing its rewarding effects. This dual action makes Varenicline Tartrate an effective therapy for smoking cessation. It is extensively used in neuropharmacology research to study nicotine addiction, dopaminergic signaling, and reward pathways, offering insights into developing treatments for addiction and other neuropsychiatric conditions involving nicotinic receptor modulation.